Switzerland has confirmed its participation in the World Health Organization (WHO)’s COVAX initiative aimed at ensuring equitable access to Covid-19 vaccines when they are approved.
The government confirmed on September 18 its participation in the initiative to secure vaccines for 20% of the population, it said in a press releaseExternal link on Friday.
“In order to secure a fair distribution of Covid-19 vaccines across the globe, nations across the world have formed the COVAX initiative (COVID-19 Vaccine Global Access Facility) and created a pooled procurement mechanism,” it explained.
More than 60 higher income economies have joined COVAX, according to a September 21 WHO press releaseExternal link. It said more were expected to sign up in coming days. They are joined by 92 low- and middle-income economies eligible for support for the procurement of vaccines. The aim is to procure two billion doses of vaccines from a range of manufacturers by the end of 2021.
Funds, procurement
Switzerland will contribute CHF20 million ($22 million), according to the government press release. In addition, so-called self-financing countries – that is, higher-income countries such as Switzerland – may contribute additional funds to secure Covid-19 vaccines for their own populations.
Switzerland has also signed a contract with the US firm Moderna Therapeutics for the purchase of 4.5 million doses of vaccine and is in conversation with other vaccine manufacturers. Bern says joining the COVAX initiative is a complementary measure to these procurement efforts.
COVAX is co-led by the Vaccine Alliance (Gavi), the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO. Switzerland has been among the initiative’s supporters from the beginning and, together with Singapore, has “led a group of likeminded countries to supervise the development of the COVAX Facility from the perspective of self-financing countries”.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19 vaccine: when, and for whom?
This content was published on
It’s the question we all want an answer to: when will there be a vaccine against Covid-19? And how is fair access being negotiated?
Switzerland pre-orders 4.5 million doses of Covid-19 vaccine
This content was published on
The Swiss government has signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of a Covid-19 vaccine currently in development.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.